Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease

Life Sciences

Volumn 58, Issue 15, 1996, Pages 1201-1207

  Sramek, John J ^a   Anand, Ravi ^b   Wardle, Thomas S ^a   Irwin, Peter ^b   Hartman, Richard D ^b   Cutler, Neal R ^a,c  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

^c NONE   (United States)

Author keywords

Alzheimer's disease; Bridging study; Phase I trials; SDZ ENA 713

Indexed keywords

CHOLINESTERASE INHIBITOR; PLACEBO; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MYALGIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VOMITING;

ENA;

EID: 0029917179     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00081-1     Document Type: Article

References (22)

1. D.M. BOWEN, P.T. FRANCIS, I.P. CHESSELL, M.T. WEBSTER, A.W. PROCTER, C.P.L.H. CHEN, M. QUME, D. NEARY, A.F. CROSS, and A.R. GREEN, Alzheimer's Disease: Clinical and Treatment Perspectives, Neal R. Cutler, Carl G. Gottfries, and Klaudius Siegfried (eds), 89-116, John Wiley & Sons, Ltd., Sussex, England (1995).
2. P. DAVIES, and A.J.F. MALONEY. Lancet ii 1403 (1976).
3. N.R. SIMS, C.C.T. SMITH, A.M. DAVISON, D.M. BOWEN, R.H.A. FLACK, J.S. SNOWDON, and D. NEARY. Lancet 1 333-335 (1980).
4. P.J. WHITEHOUSE, D.L. PRICE, R.G. STRUBLE, A. CLARK, J. COYLE, and M. DELONG. Science 215 1237 (1982).
5. A. ENZ, R. AMSTUTZ, H. BODDEKE, G. GMELIN, and J. MALANOWSKY. Prog Brain Res 98 431-438 (1993).
6. G. MCKHANN, D. DRACHMAN, M. FOLSTEIN, R. KATZMAN, D. PRICE, and E.M. STADLAN. Neurology 34 939-44 (1984).
7. M.F. FOLSTEIN, S.E. FOLSTEIN, and P.R. MCHUGH. J Psychiatr Res 12 189-98 (1975).
8. V.C. HACHINSKI, L.D. ILIFF, E. ZILHKA, et al. Arch Neurol 32 632-37 (1975).
9. M.R. GOLDBERG, A. BARCHOWSKY, J. MCCREA, et al. Heptylphysostigmine (L-693,487): safety and cholinesterase inhibition in a placebo-controlled rising-dose healthy volunteer study. Presented to the Second International Springfield Symposium on Advances in Alzheimer Therapy, May 1991.
10. N.R. CUTLER, J.J. SRAMEK, G. BLOCK, et al. Life Sciences 56 PL19-PL25 (1994).
11. P.A. REECE, H. BOCKBRADER, and A.J. SEDMAN. Clin Exp Pharmacol Physiol 21(Suppl) 58 (1992).
12. J.J. SRAMEK, A.J. SEDMAN, P.A. REECE, J. HOURANI, J. BOCKBRADER, and N.R. CUTLER. Life Sciences 57 503-510 (1995).
13. S.K. PURI, I. HO, H.B. LASSMAN. J Clin Pharmacol 30 948-955 (1990).
14. N.R. CUTLER, M.F. MURPHY, R.J. NASH, P.L. PRIOR, and D.M. DELUNA. J Clinical Pharmacol 30 556-561 (1990).
15. J.J. SRAMEK, D.J. HURLEY, T.S. WARDLE, J.H. SATTERWHITE, J. HOURANI, F. DIES, and N.R. CUTLER. J Clin Pharm 35 800-806 (1995).
16. L.F.M. SCINTO, K.R. DAFFNER, D. DRESSLER, et al. Science 266 1051-1054 (1994).
17. N.R. CUTLER and J.J. SRAMEK. Alzheimer Dis Assoc Disord 9 139-145 (1995).
18. K.L. DAVIS, L.J. THAL, E.R. GAMZU, C.S. DAVIS, R.F. WOOLSON, S.I. GRACON, D.A. DRACHMAN, L.S. SCHNEIDER, P.J. WHITEHOUSE, T.M. HOOVER, J.C. MORRIS, C.H. KAWAS, D.S. KNOPMAN, N.L. EARL, V. KUMAR, and R.S. DOODY. N Engl J Med 327 1253-1259 (1992).
19. M. FARLOW, S.I. GRACON, L.A. HERSHEY, K.W. LEWIS, C.H. SADOWSKY, and J. DOLAN-URENO. JAMA 268 2523-2529 (1992).
20. W.K. SUMMERS, L.V. MAJOVSKI, G.M. MARSH, K. TACHIKI, and A. KLING. N Engl J Med 315 1241-1245 (1986).
21. M.J. KNAPP, D.S. KNOPMAN, P.R. SOLOMON, et al. JAMA 271 985-991 (1994).
22. N.R. CUTLER, J.J. SRAMEK. Eur J Clin Pharmacol 48 421-428 (1995).